SUSMED, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Peptidream, Inc.

Cyfuse Biomedical KK

MEDINET Co., Ltd.

OncoTherapy Science, Inc.

Oncolys BioPharma, Inc.

Chiome Bioscience, Inc.

Carna Biosciences, Inc.

SUSMED, Inc.

GNI Group Ltd.

StemCell Institute

Stella Pharma Corp.

Why is SUSMED, Inc. ?

Poor Management Efficiency with a low ROE of 0.04%

The company has been able to generate a Return on Equity (avg) of 0.04% signifying low profitability per unit of shareholders funds

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0.04%

Negative results in Mar 26

NET SALES(HY) At JPY 184.87 MM has Grown at -52.13%
NET PROFIT(HY) At JPY -210.77 MM has Grown at -1,149.8%
ROCE(HY) Lowest at -11.25%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 33.22%, its profits have risen by 53.1%

Underperformed the market in the last 1 year

The stock has generated a return of 33.22% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 85.83%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is SUSMED, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

SUSMED, Inc.

33.22%

0.62

67.92%

Japan Nikkei 225

85.83%

3.09

27.80%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

55.14%

EBIT Growth (5y)

7.91%

EBIT to Interest (avg)

-215.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.09

Tax Ratio

0.43%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

0.04%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.12

EV to EBIT

-47.20

EV to EBITDA

-48.57

EV to Capital Employed

90.31

EV to Sales

27.25

PEG Ratio

Dividend Yield

ROCE (Latest)

-191.32%

ROE (Latest)

-6.51%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET PROFIT(HY)

Higher at JPY -210.77 MM

RAW MATERIAL COST(Y)

Fallen by 0.95% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 196.08 times

NET SALES(Q)

At JPY 139.43 MM has Grown at 16.05%

-19What is not working for the Company

NET SALES(HY)

At JPY 184.87 MM has Grown at -52.13%

NET PROFIT(HY)

At JPY -210.77 MM has Grown at -1,149.8%

ROCE(HY)

Lowest at -11.25%

DEBT-EQUITY RATIO (HY)

Highest at -96.33 %

Here's what is working for SUSMED, Inc.

Net Profit

Higher at JPY -210.77 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

Net Sales

At JPY 139.43 MM has Grown at 16.05%

over average net sales of the previous four periods of JPY 120.15 MM

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Inventory Turnover Ratio

Highest at 196.08 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by 0.95% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for SUSMED, Inc.

Net Profit

At JPY -210.77 MM has Grown at -1,149.8%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (JPY MM)

Debt-Equity Ratio

Highest at -96.33 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio